Peter S. Greenleaf
|Age||Total Calculated Compensation||This person is connected to 124 board members in 4 different organizations across 9 different industries.|
See Board Relationships
Mr. Peter S. Greenleaf has been the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and March 03, 2014 respectively. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune, LLC (also known as MedImmune, Inc.). He also served as President of MedImmune Ventures, a wholly owned venture capital fund within ...
One MedImmune WayPhone: 301-398-3000
Gaithersburg, Maryland 20878
Board Members Memberships*
Chairman and Chief Executive Officer
Saint Joseph's University
Western Connecticut State University
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Michael W. Aguiar||Chief Executive Officer, President and Director|
|Mark R. Baker J.D.||Chief Executive Officer, Director and Member of Science Committee|
Progenics Pharmaceuticals, Inc.
|Craig A. Wheeler||Chief Executive Officer, President and Executive Director|
Momenta Pharmaceuticals, Inc.
|A. J. Kazimi MBA||Founder, Chairman, Chief Executive Officer and President|
Cumberland Pharmaceuticals Inc.
|John Anthony Sedor||Chairman and Chief Executive Officer|
Pernix Therapeutics Holdings, Inc.
|--||Compensation as of Fiscal Year 2015.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.